Urea Cycle Disorders Market to Expand at a Substantial Growth Rate During the Forecast Period (2019-32) - Estimates DelveInsight | Key Companies - Acer Therapeutics/Relief Therapeutics (OLPRUVA/ sodium phenylbutyrate), ACER-001 (Acer Therapeutics), Aeglea

As per DelveInsight's assessment, the Urea Cycle Disorders Market is anticipated to grow in the coming years owing to the increasing incidence of Urea Care Disorders patients in the 7MM and the launch of emerging therapies in the market. Some of the key players involved in the development of novel drugs for the treatment of Urea Cycle Disorders include ACER-001 (Acer Therapeutics), AEB1102 (Aeglea BioTherapeutics), DTX301 (Ultragenyx Pharmaceutical), among others.

DelveInsight's "Urea Cycle Disorders Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Urea Cycle Disorders Market Size and Share in the 7MM (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Urea Cycle Disorders market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Urea Cycle Disorders: An Overview
Urea cycle disorders (UCDs) are a congenital error of nitrogen detoxification/arginine synthesis due to defects in the urea cycle enzymes such as carbamoylphosphate synthetase 1 (CPS1), ornithine transcarbamylase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL) and arginase 1 (ARG1), leading to respective deficiencies (abbreviated CPS1D, OTCD, ASSD, ASLD, and ARG1D).

All the urea cycle disorders are inherited in an autosomal recessive pattern, except ornithine transcarbamoylase (OTC) deficiency, which is inherited as an X-linked trait; however, female carriers of the OTC gene can become symptomatic.

Urea Cycle Disorders Market Key Facts
- The prevalence of Urea Cycle Disorders in the US is approximately 1 in 35,000, with two-thirds having symptoms in the neonatal period. The mortality rate of Urea Cycle Disorders is 24% in neonatal cases and 11% in later onset cases (Van Leung-Pineda (2019)).
- According to Mageed G (2015), the prevalence of Urea Cycle Disorders in EU-5 was 1.89 per 100,000 in the 0-4-year-old age group, 1.63 per 100,000 in the 10-14-year-old age group, and 1.57 per 100,000 in the 15-17-year-old age group.
- As per the NORD, OTC deficiency affects males more often than females, and most males are symptomatic in nature. In males, symptoms typically begin during the first few days of life.
- According to Kido et al. (2021), the estimated prevalence of Urea Cycle Disorders is 1 per 50,000 live births in Japan.

Urea Cycle Disorders Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Urea Cycle Disorders market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Urea Cycle Disorders market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Urea Cycle Disorders Market will Grow by 2032:
https://www.delveinsight.com/report-store/urea-cycle-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Urea Cycle Disorders Epidemiology
The epidemiology section covers detailed insights into the historical and current Urea Cycle Disorders patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Urea Cycle Disorders Epidemiology, Segmented by -
- Total Incident Cases of Urea Cycle Disorders in the 7MM
- Onset-specific cases of Urea Cycle Disorders in the 7MM
- Total Incident Cases of Urea Cycle Disorders by types in the 7MM
- Diagnosed and treatable Cases of Urea Cycle Disorders by types in the 7MM

Get Key Insights Into the Evolving Urea Cycle Disorders Epidemiology Trends:
https://www.delveinsight.com/report-store/urea-cycle-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Urea Cycle Disorders Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Urea Cycle Disorders market or expected to be launched during the study period. The analysis covers Urea Cycle Disorders market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Urea Cycle Disorders Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/urea-cycle-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Urea Cycle Disorders Therapeutics Assessment
There are approx. 8+ key companies developing therapies for Urea Cycle Disorders. Currently, Acer Therapeutics is leading the therapeutics market with its Urea Cycle Disorders drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Urea Cycle Disorders Therapeutics Market Include:
- Acer Therapeutics
- Dimension Therapeutics
- Callitas Therapeutics
- Poseida Therapeutics
- Promethera Biosciences
- Arcturus Therapeutics
- Kaleido Biosciences
- Akaza Biopharma
- Evox Therapeutics
- Dipharma SA
- Sana Biotechnology
- Aeglea BioTherapeutics
- ERYTECH
And Many More

Urea Cycle Disorders Emerging Therapies Covered in the Report Include:
- ACER-001: Acer Therapeutics
- AEB1102: Aeglea BioTherapeutics
- DTX301: Ultragenyx Pharmaceutical
- Avalotcagene ontaparvovec: Dimension Therapeutics
And Many Others

Learn More About the Emerging Therapies & Key Companies in the Urea Cycle Disorders Therapeutics Market:
https://www.delveinsight.com/sample-request/urea-cycle-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Urea Cycle Disorders Competitive Intelligence Analysis
4. Urea Cycle Disorders Market Overview at a Glance
5. Urea Cycle Disorders Background and Overview
6. Urea Cycle Disorders Patient Journey
7. Urea Cycle Disorders Epidemiology and Patient Population
8. Urea Cycle Disorders Treatment Algorithm, Current Treatment, and Medical Practices
9. Urea Cycle Disorders Unmet Needs
10. Key Endpoints of Urea Cycle Disorders Treatment
11. Urea Cycle Disorders Marketed Products
12. Urea Cycle Disorders Emerging Therapies
13. Urea Cycle Disorders Seven Major Market Analysis
14. Attribute Analysis
15. Urea Cycle Disorders Market Outlook (7 major markets)
16. Urea Cycle Disorders Access and Reimbursement Overview
17. KOL Views on the Urea Cycle Disorders Market.
18. Urea Cycle Disorders Market Drivers
19. Urea Cycle Disorders Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/urea-cycle-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/urea-cycle-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Trending Market Research Reports 2032 | DelveInsight

Technical Due Diligence Firms- https://www.delveinsight.com/consulting/due-diligence-services

Vital Sign Monitors Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market

Anastomosis Device Market- https://www.delveinsight.com/report-store/anastomotic-leak-devices-market

Asperger Syndrome Market- https://www.delveinsight.com/report-store/asperger-syndrome-market

B-Cell Maturation Antigen Targeted Therapies Market- https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market

UK Healthcare Report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report

Oncolytic Virus Cancer Therapy Pipeline- https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Shingles Market- https://www.delveinsight.com/report-store/shingles-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

This release was published on openPR.